Latest Insider Transactions at Aurinia Pharmaceuticals Inc. (AUPH)
This section provides a real-time view of insider transactions for Aurinia Pharmaceuticals Inc. (AUPH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Aurinia Pharmaceuticals Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Aurinia Pharmaceuticals Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 02
2023
|
Peter Greenleaf Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
667,407
+39.65%
|
-
|
|
Mar 02
2023
|
Volker Knappertz EVP, Research and Development |
BUY
Grant, award, or other acquisition
|
Direct |
191,462
+35.74%
|
-
|
|
Mar 02
2023
|
Scott Michael Habig Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
170,188
+35.24%
|
-
|
|
Mar 02
2023
|
Michael Robert Martin Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
107,202
+29.26%
|
-
|
|
Mar 02
2023
|
Stephen P. Robertson EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
19,402
-6.01%
|
$155,216
$8.94 P/Share
|
|
Mar 02
2023
|
Stephen P. Robertson EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
204,810
+38.82%
|
-
|
|
Mar 02
2023
|
Joseph M Miller Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,296
-3.3%
|
$90,368
$8.94 P/Share
|
|
Mar 02
2023
|
Joseph M Miller Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
229,421
+40.11%
|
-
|
|
Mar 02
2023
|
Matthew Maxwell Donley EVP, Ops & Strategy |
BUY
Grant, award, or other acquisition
|
Direct |
271,134
+40.21%
|
-
|
|
Nov 21
2022
|
Matthew Maxwell Donley EVP, Ops & Strategy |
BUY
Open market or private purchase
|
Direct |
10,000
+26.37%
|
$40,000
$4.66 P/Share
|
|
Nov 09
2022
|
Scott Michael Habig Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$25,000
$5.01 P/Share
|
|
Nov 07
2022
|
Michael Robert Martin Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+25.1%
|
$150,000
$5.16 P/Share
|
|
Mar 09
2022
|
R. Hector Mac Kay Dunn |
BUY
Open market or private purchase
|
Direct |
5,000
+31.25%
|
$55,000
$11.0 P/Share
|
|
Mar 04
2022
|
George M Milne Jr Director |
BUY
Open market or private purchase
|
Direct |
5,000
+9.09%
|
$50,000
$10.82 P/Share
|
|
Mar 02
2022
|
Robert Bindert Huizinga EVP of Research |
SELL
Open market or private sale
|
Direct |
4,849
-6.53%
|
$58,188
$12.01 P/Share
|
|
Mar 02
2022
|
Robert Bindert Huizinga EVP of Research |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+10.27%
|
-
|
|
Mar 02
2022
|
Neil Solomons Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,846
-5.06%
|
$58,152
$12.01 P/Share
|
|
Mar 02
2022
|
Neil Solomons Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+8.15%
|
-
|
|
Mar 02
2022
|
Stephen P. Robertson EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+42.12%
|
-
|
|
Mar 02
2022
|
Peter Greenleaf Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,068
-21.57%
|
$108,816
$12.01 P/Share
|
|
Mar 02
2022
|
Peter Greenleaf Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,300
+40.24%
|
-
|
|
Mar 02
2022
|
Massimilano Colao Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,205
-19.19%
|
$38,460
$12.01 P/Share
|
|
Mar 02
2022
|
Massimilano Colao Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+33.73%
|
-
|
|
Mar 02
2022
|
Joseph M Miller Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,060
-31.64%
|
$36,720
$12.01 P/Share
|
|
Mar 02
2022
|
Joseph M Miller Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+46.78%
|
-
|
|
Mar 02
2022
|
Matthew Maxwell Donley EVP, Ops & Strategy |
SELL
Open market or private sale
|
Direct |
3,052
-15.83%
|
$36,624
$12.01 P/Share
|
|
Mar 02
2022
|
Matthew Maxwell Donley EVP, Ops & Strategy |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+30.6%
|
-
|
|
Mar 02
2022
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,849
-7.53%
|
$58,188
$12.01 P/Share
|
|
Mar 02
2022
|
Michael Robert Martin Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+11.67%
|
-
|
|
Jan 03
2022
|
Joseph P Hagan Director |
SELL
Open market or private sale
|
Direct |
40,000
-52.92%
|
$880,000
$22.94 P/Share
|
|
Jan 03
2022
|
Joseph P Hagan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+47.9%
|
$200,000
$5.08 P/Share
|
|
Dec 13
2021
|
Jill Leversage Director |
BUY
Open market or private purchase
|
Direct |
1,600
+23.19%
|
$32,000
$20.04 P/Share
|
|
Nov 11
2021
|
Neil Solomons Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
100,000
-53.39%
|
$2,800,000
$28.89 P/Share
|
|
Nov 11
2021
|
Neil Solomons Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+34.81%
|
$500,000
$5.3 P/Share
|
|
Nov 11
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
11,000
-16.45%
|
$319,000
$29.5 P/Share
|
|
Nov 11
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
29,000
-30.25%
|
$812,000
$28.82 P/Share
|
|
Nov 11
2021
|
Michael Robert Martin Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
29,000
+23.23%
|
$522,000
$18.38 P/Share
|
|
Nov 10
2021
|
Neil Solomons Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
100,000
-29.16%
|
$3,000,000
$30.86 P/Share
|
|
Nov 10
2021
|
Neil Solomons Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+22.3%
|
$500,000
$5.68 P/Share
|
|
Nov 10
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
60,000
-26.21%
|
$1,800,000
$30.91 P/Share
|
|
Nov 09
2021
|
Neil Solomons Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
50,000
-36.42%
|
$1,500,000
$30.17 P/Share
|
|
Nov 09
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
50,000
-28.27%
|
$1,500,000
$30.17 P/Share
|
|
Nov 01
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
45,000
-20.28%
|
$1,395,000
$31.64 P/Share
|
|
Nov 01
2021
|
Michael Robert Martin Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+16.86%
|
$135,000
$3.2 P/Share
|
|
Nov 01
2021
|
Neil Solomons Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
45,000
-24.68%
|
$1,395,000
$31.64 P/Share
|
|
Nov 01
2021
|
Neil Solomons Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+19.8%
|
$225,000
$5.3 P/Share
|
|
Oct 25
2021
|
Robert Bindert Huizinga EVP of Research |
SELL
Open market or private sale
|
Direct |
130,000
-66.42%
|
$3,770,000
$29.75 P/Share
|
|
Oct 25
2021
|
Robert Bindert Huizinga EVP of Research |
BUY
Exercise of conversion of derivative security
|
Direct |
95,000
+32.68%
|
$285,000
$3.2 P/Share
|
|
Sep 21
2021
|
Robert Bindert Huizinga EVP of Research |
SELL
Open market or private sale
|
Direct |
32,500
-12.71%
|
$747,500
$23.86 P/Share
|
|
Sep 21
2021
|
Robert Bindert Huizinga EVP of Research |
BUY
Exercise of conversion of derivative security
|
Direct |
27,136
+9.65%
|
$54,272
$2.92 P/Share
|